An obesity expert criticizes the widespread practice of compounding GLP-1 medications, arguing that many online sellers exploit regulatory loopholes for profit rather than genuine medical necessity. The expert emphasizes that compounded drugs lack the rigorous oversight of approved medicines, leading to potential sterility failures and dosing errors. They call for the FDA to issue clearer guidance, stating that cost is not a valid reason for compounding and that these alternatives are not equivalent to approved GLP-1s, urging prescribers to cease the practice without clear medical justification. AI
RANK_REASON Expert opinion piece discussing a trend and calling for regulatory action.
- diabetes
- eating disorder
- GLP-1
- obesity
- sleep apnea
- United States Food and Drug Administration
- vitamin B12
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
